Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Glucagon is commonly used during gastrointestinal examinations for the temporary inhibition of gastroduodenal movements. Three preparations of glucagon are now clinically available: those prepared by extraction from the pancreas (GL-P), by chemical synthesis (GL-S), and by genetic recombination (GL-G). The aim of this study was examine the mechanism of the inhibitory effect of glucagon on gastrointestinal motility and the cause of its side effects by comparing three glucagon preparations. In four conscious dogs, gastrointestinal contractions were monitored by means of chronically implanted force transducers. Each glucagon preparation (GL-P [15 microg/kg], GL-S [5, 15, 45 microg/kg], GL-G [15 microg/kg]), scopolamine butylbromide (0.4 mg/ kg), or saline was administered intravenously 20 min after the termination of spontaneous phase III contractions, and blood samples were taken at 5- to 10-min intervals. Barium was administered into the stomach 10 min after the infusion of each drug. The arrival of a barium meal in the stomach immediately stimulated gastrointestinal contractions, and the barium meal was expelled into the duodenum and jejunum from the stomach. Intravenous injection of 15 microg GL-S first stimulated duodenal contractions that propagated to the jejunum, followed by strong inhibition of the barium-induced gastrointestinal contractions. This inhibitory effect of glucagon and the activity of the glucagon-induced duodenal contractions were dose-related. The inhibitory effects of GL-G and GL-S were stronger than that of GL-P. Blood glucose and plasma insulin concentrations were raised after intravenous injection of each glucagon preparation, but there was no difference among the three preparations and no dose relationship. The inhibitory effects of glucagon depend on the material purity and dose, and the inhibitory mechanism was independent of any effect on carbohydrate metabolism. Glucagon administration caused phase III-like contractions in the duodenum and jejunum, which may be responsible for the side effects of glucagon.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucagon also has the ability to inhibit gastric motility29 and promote renal glomerular filtration30, with notable effects evident on the cardiovascular system to increase heart rate, cardiac contractility and cardiac output31 (Figure 1).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [29]
Citations
Cites
The Mechanism of Satiety: Effect of Glucagon on Gastric Hunger Contractions in Man.
Stunkard, A. J., Van Itallie, T. B., & Reis, B. B. (1955) · Experimental Biology and Medicine · doi:10.3181/00379727-89-21776 · Cited by 160
Hypotonic Duodenography with the Use of Glucagon
Chernish, S. M., Miller, R. E., Rosenak, B. D., & Scholz, N. (1972) · Gastroenterology · doi:10.1016/s0016-5085(19)33276-7 · Cited by 74
Effect of glucagon on gastrointestinal motility.
NECHELES, H., Sporn, J., & Walker, L. (1966) · PubMed · Cited by 73
The Effect of Glucagon on Intestinal Motility in Man
Dotevall, G., & Kock, N. G. (1963) · Gastroenterology · doi:10.1016/s0016-5085(19)34888-7 · Cited by 59
Cameron, A. J., Phillips, S. F., & Summerskill, W. H. J. (1970) · Gastroenterology · doi:10.1016/s0016-5085(19)33707-2 · Cited by 54
Solid-phase synthesis of crystalline glucagon
Mojsov, S., & Merrifield, R. B. (1981) · Biochemistry · doi:10.1021/bi00513a036 · Cited by 46
HYPOTONIC ROENTGENOGRAPHY WITH GLUCAGON
MILLER, R. E., CHERNISH, S. M., SKUCAS, J., ROSENAK, B. D., & RODDA, B. E. (1974) · American Journal of Roentgenology · doi:10.2214/ajr.121.2.264 · Cited by 45
An improved synthesis of crystalline mammalian glucagon
Mojsov, S., & Merrifield, R. B. (1984) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1984.tb08599.x · Cited by 39
The Effect of Glucagon on Intestinal Motility and Blood Flow
Fasth, S., & Hultén, L. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1971.tb05066.x · Cited by 39
Mochiki, E., Satoh, M., Tamura, T., Haga, N., Suzuki, H., Mizumoto, A., Sakai, T., & Itoh, Z. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70006-9 · Cited by 33
Self-citation
Cited by
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“These activities include central regulation of energy intake (60, 131, 517), stimulation of brown fat thermogenesis (151, 321, 371), inhibition of gastric motility (433, 545, 620), modulation of lipid metabolism through activation of lipolysis and inhibition of lipid synthesis (19, 95, 136, 167, 476, 518), improvement…”
BackgroundCoskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Insulin as a physiological modulator of glucagon secretion
Bansal, P., & Wang, Q. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90295.2008 · Cited by 150
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
The Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
“Glucagon may directly or indirectly increase heart rate [123], renal excretion of electrolytes [124] and gastric emptying [125]/peristalsis [126].”
BackgroundGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
Insuela, D. B. R., & Carvalho, V. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.015 · Cited by 72
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes
Marroquí, L., Alonso-Magdalena, P., Merino, B., Fuentes, E., Nadal, A., & Quesada, I. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000031 · Cited by 54
Glucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
“infusion resulted in jejunal dilatation and increased mean transit time in humans,(86,87) independent of its effect on carbohydrate metabolism.(84) Nevertheless, Mochiki et al.”
BackgroundInfluentialOral peppermint oil is a useful antispasmodic for double‐contrast barium meal examination
Mizuno, S., Kato, K., Ono, Y., Yano, K., Kurosaka, H., Takahashi, A., Abeta, H., Kushiro, T., Miyamoto, S., Kurihara, R., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04131.x · Cited by 42
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
Erythritol-based dry powder of glucagon for pulmonary administration
Endo, K., Amikawa, S., Matsumoto, A., Sahashi, N., & Onoue, S. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.018 · Cited by 35
Katoh, K., Nomura, M., Iga, A., Hiasa, A., Uehara, K., Harada, K., Nakaya, Y., & Ito, S. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-003-1114-y · Cited by 34
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
PARKINSON, J. R., Muthas, D., Clark, M., Boyer, S. K., Valentin, J., & Ewart, L. C. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr334 · Cited by 27
Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W. (2024) · Endocrine · doi:10.1007/s12020-024-03998-8 · Cited by 21
Geng, R., Zhang, Y., Starekova, J., Rutkowski, D. R., Estkowski, L. D., Roldán‐Alzate, A., & Hernando, D. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28846 · Cited by 21
Glucagon stimulation test for estimating endogenous insulin secretion in dogs
Fall, T., Holm, B., Karlsson, Å., Ahlgren, K. M., Kämpe, O., & von Euler, H. (2008) · Veterinary Record · doi:10.1136/vr.163.9.266 · Cited by 21
Berg, J. K., Kim, E. H., Li, B. C., Joelsson, B. E., & Youssef, N. N. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-25 · Cited by 24
Onoue, S., Kuriyama, K., Uchida, A., Mizumoto, T., & Yamada, S. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0379-8 · Cited by 19
Translational aspects of glucagon: current use and future prospects
Kaur, J., & Seaquist, E. R. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0278 · Cited by 21
Américo, M. F., Miranda, J. R. D. A., Corá, L. A., & Romeiro, F. G. (2009) · Physiological Measurement · doi:10.1088/0967-3334/30/4/002 · Cited by 16
Onoue, S., Yamamoto, K., Kawabata, Y., Hirose, M., Mizumoto, T., & Yamada, S. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.024 · Cited by 16
An ingestible self-propelling device for intestinal reanimation
Srinivasan, S. S., Dosso, J., Huang, H., Selsing, G., Alshareef, A. A., Kuosmanen, J. L. P., Ishida, K., Jenkins, J. A., Madani, W. A. M., Hayward, A. M., et al. (2024) · Science Robotics · doi:10.1126/scirobotics.adh8170 · Cited by 15
Pharmacological and mechanical management of calcium channel blocker toxicity
Fadhlillah, F., & Patil, S. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-225324 · Cited by 15
From Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes
Guimarães, M., Pereira, S. S., & Monteiro, M. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_480 · Cited by 9
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Fujinami, H., Kajiura, S., Nishikawa, J., Ando, T., & Sugiyama, T. (2017) · Chinese Medicine · doi:10.1186/s13020-016-0125-6 · Cited by 4
Glucagon-Induced Vasospasm of Hepatic Artery Branches During Visceral Angiography
Dziedzic, T. S., & Smith, T. P. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-007-9172-9 · Cited by 3
Farmacomagnetografia colônia: estudo in vitro da desintegração de comprimidos magnéticos revestidos
Andreis, U. (2010) · Americanae (AECID Library) · Cited by 1
Metadata
- Authors
- Mochiki, E., Suzuki, H., Takenoshita, S., Nagamachi, Y., Kuwano, H., Mizumoto, A., & Itoh, Z.
- Affiliations
- Gunma University (JP)
- Venue
- Journal of Gastroenterology
- Published
- 1998-11-05
- Volume
- 33
- Issue
- 6
- Pages
- 835-841
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2038548962
- Cited by
- 38
- References
- 18
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 1 · 2014: 2
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon, gastrointestinal motility, pancreatic glucagon, barium meal, duodenal contractions, jejunum, phase III contractions, adverse effects, blood glucose, plasma insulin, scopolamine
- MeSH terms
- Analysis of Variance, Animals, Blood Glucose, Digestive System, Dogs, Dose-Response Relationship, Drug, Drug Compounding, Gastrointestinal Agents, Gastrointestinal Motility, Glucagon, Injections, Intravenous, Insulin, Muscle Contraction, Radiography, Reference Values
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.